{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Okato A"],"funding":["Hitoshi Ishikawa"],"pagination":["3039"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12469118"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(18)"],"pubmed_abstract":["<b>Background/Objectives</b>: Carbon-ion radiotherapy (CIRT) offers precise dose distribution and enhanced biological effectiveness in localized prostate cancer. However, the safety of CIRT in patients with a history of surgery for benign prostatic hyperplasia (BPH), such as transurethral resection of the prostate (TURP), remains unclear. This study aimed to evaluate the long-term safety and oncological outcomes of CIRT in this population. <b>Methods:</b> A retrospective analysis was conducted in 74 of 3848 patients with prostate cancer and a history of surgery for BPH who underwent CIRT combined with risk-adapted androgen deprivation therapy between 2007 and 2023. Adverse events were assessed using CTCAE v5.0. Biochemical recurrence-free survival was estimated using the Kaplan-Meier metho"],"journal":["Cancers"],"pubmed_title":["Carbon-Ion Radiotherapy for Prostate Cancer in Patients with a History of Surgery for Benign Prostatic Hyperplasia."],"pmcid":["PMC12469118"],"funding_grant_id":["JP24K10899"],"pubmed_authors":["Okato A","Miura K","Yamaguchi T","Utsumi T","Tsuji H","Ichikawa T","Nakajima M","Makishima H","Akakura K","Wakatsuki M","Suzuki H","Ishikawa H"],"additional_accession":[]},"is_claimable":false,"name":"Carbon-Ion Radiotherapy for Prostate Cancer in Patients with a History of Surgery for Benign Prostatic Hyperplasia.","description":"<b>Background/Objectives</b>: Carbon-ion radiotherapy (CIRT) offers precise dose distribution and enhanced biological effectiveness in localized prostate cancer. However, the safety of CIRT in patients with a history of surgery for benign prostatic hyperplasia (BPH), such as transurethral resection of the prostate (TURP), remains unclear. This study aimed to evaluate the long-term safety and oncological outcomes of CIRT in this population. <b>Methods:</b> A retrospective analysis was conducted in 74 of 3848 patients with prostate cancer and a history of surgery for BPH who underwent CIRT combined with risk-adapted androgen deprivation therapy between 2007 and 2023. Adverse events were assessed using CTCAE v5.0. Biochemical recurrence-free survival was estimated using the Kaplan-Meier metho","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-05-02T03:10:28.162Z","creation":"2026-05-02T03:07:38.482Z"},"accession":"S-EPMC12469118","cross_references":{"pubmed":["41008882"],"doi":["10.3390/cancers17183039"]}}